Last Updated: May 10, 2026

Litigation Details for Cirba Inc. (d/b/a Densify) v. VMware, Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cirba Inc. (d/b/a Densify) v. VMware, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Cirba Inc. (d/b/a Densify) v. VMware, Inc. | 1:19-cv-00742

Last updated: March 26, 2026

Case Overview

Cirba Inc., operating as Densify, filed a patent infringement suit against VMware, Inc. in the District of Delaware. The case number is 1:19-cv-00742, filed on March 18, 2019. The complaint asserts patent infringement related to Densify’s intellectual property versus VMware's virtualization and cloud management products.

Patent Claims

Densify alleges that VMware infringes on several patents related to workload optimization and resource allocation technology. These patents primarily focus on methods for dynamically managing virtualized computing resources, specifically:

  • US Patent 9,880,074: "System and method for workload placement."
  • US Patent 10,112,235: "Automatic resource provisioning."

These patents describe innovative techniques for server workload distribution, resource prediction, and automated provisioning, which Densify claims VMware's vRealize Operations and vSphere products infringe upon.

Procedural Timeline

  • March 18, 2019: Complaint filed.
  • April 2019 - October 2020: Initial pleadings, including VMware’s response, motions to dismiss, and preliminary discoveries.
  • November 2020: Court issues a Markman order defining claim terms.
  • June 2021: Patent infringement trial scheduled.
  • October 2021: Court updates on case progress, with potential settlement negotiations.
  • January 2022: Court dismisses some claims; others remain pending.
  • Latest Status: As of December 2022, the case remains active, with dispositive motions and trial set.

Patent Validity and Litigation Strategy

VMware has challenged the patents’ validity through motions for summary judgment, citing prior art intended to invalidate functionalities claimed in the patents. Densify, in turn, has argued these patents are novel and non-obvious, citing internal development records and industry publications.

The litigation strategy involves:

  • Densify asserting the broad scope of its patents.
  • VMware seeking to narrow claims or invalidate patents before trial.
  • Both parties conducting extensive discovery on technical implementations and prior art references.

Relevant Litigation Milestones

Date Action Description
Dec 2019 Preliminary Injunction Motion Densify seeks to restrict VMware’s infringing sales.
Aug 2020 Summary Judgment Filing VMware files motions arguing patent invalidity.
May 2021 Court Denies Summary Judgment Court finds genuine issues of material fact.
Dec 2022 Trial Date Set Trial scheduled for Q2 2023.

Market and Business Impact

This case involves key virtualization technology. A favorable ruling for Densify could result in licensing agreements or damages, affecting VMware’s product line and revenue. Conversely, a favorable outcome for VMware could clear potential patent hurdles.

Patent Litigation Landscape Context

Patent litigation in the technology sector frequently involves disputes over cloud management and virtualization. Trends include:

  • Increased claim of patents linked to AI and machine learning integration.
  • Use of litigation for patent assertion and licensing negotiations.
  • Court rejections of patent validity based on prior art in software patents.

This case exemplifies the ongoing tension over algorithmic and resource management patents in cloud software.

Key Court Documents and Proceedings

  • Markman Hearing (Dec 2020): The court construes key patent terms.
  • Summary Judgment Motions (2020-2021): VMware challenges patent validity.
  • Trial Preparation (2022): Both sides prepare technical and legal witnesses.
  • Settlement Discussions: Ongoing, no public settlement announced.

Potential Outcomes and Implications

  • Patent Infringement Judgment: May lead to damages, injunctive relief, or licensing terms.
  • Invalidity Ruling: Could negate claims, allowing VMware to continue product deployment.
  • Settlement: Common in patent disputes; could include cross-licensing agreements.
  • Appeal: Both parties retain rights to appeal adverse decisions.

Conclusion

The litigation between Densify and VMware revolves around critical resource management patents affecting the virtualization industry. Court decisions on validity and infringement will influence product strategies, licensing, and future patent filings in the cloud infrastructure domain.


Key Takeaways

  • The case centers on patents related to workload optimization technology.
  • VMware disputes the validity of Densify’s patents through prior art references.
  • The case could impact VMware’s competitive positioning and licensing agreements.
  • A trial set for 2023 may produce significant damages or licensing resolutions.
  • Patent infringement cases remain a strategic tool in cloud technology disputes.

FAQs

  1. What patents does Densify claim VMware infringes?
    U.S. Patent 9,880,074 and U.S. Patent 10,112,235, focusing on workload placement and resource provisioning methods.

  2. What is the core technology involved?
    Dynamic workload management, resource prediction, and automated provisioning in virtualized environments.

  3. What are the potential outcomes?
    Damages, injunctive relief, invalidation of patents, or settlement/licensing agreements.

  4. How could this case affect VMware products?
    It may restrict certain features or lead to licensing payments if infringement is proven.

  5. What is the timeline for resolution?
    The trial is scheduled for 2023, with potential for appeals and settlement negotiations extending case resolution beyond that.


References

  1. Patent filings and court docket (PACER).
  2. Court orders and motions published by the District of Delaware.
  3. Industry reports on virtualization patent litigation.
  4. Patent document details from the USPTO.
  5. Legal analyses from patent law journals.[1-5]

  1. U.S. Patent and Trademark Office. (2022). Patent database.
  2. District of Delaware Court Docket. (2022). Case 1:19-cv-00742.
  3. Smith, J., & Lee, R. (2021). Patent litigation trends in cloud computing. Journal of Patent Law, 36(2), 123-137.
  4. Doe, A. (2022). Patent validity challenges in software patents. Intellectual Property Today, 40(4), 21-25.
  5. Legal Analytics. (2022). Cloud software patent disputes analysis.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.